By Fineline Cube Shenzhen Hybio Pharmaceutical Co., Ltd. (SHE: 300199) announced that it has signed a collaboration agreement with Zhejiang Wansheng Pharmaceutical Co., Ltd. (“Wansheng Pharmaceutical”) for the glycemic control indication of Hybio’s semaglutide — a generic drug referencing Novo Nordisk’s Ozempic/Wegovy with Phase 3 studies already completed. The two parties had previously entered into a collaboration in May 2024 for the weight management indication of Hybio’s semaglutide, making this the second indication-specific agreement between the companies.
Deal Terms
| Item | Detail |
|---|---|
| Licensor | Shenzhen Hybio Pharmaceutical Co., Ltd. (SHE: 300199) |
| Licensee | Zhejiang Wansheng Pharmaceutical Co., Ltd. |
| Asset | Semaglutide (generic referencing Ozempic/Wegovy) — glycemic control indication |
| License Scope | Exclusive, non-transferable, sub-licensable license in Mainland China, Hong Kong, and Macau |
| Licensee Role | Marketing Authorization Holder (MAH); solely responsible for commercialization |
| Upfront Payment | RMB 12 million |
| Approval Milestone | RMB 18 million upon regulatory approval for glycemic control |
| Supply Milestone | RMB 7.5 million upon first commercial batch delivery |
| Sales Milestones | Up to RMB 145 million |
| Royalties | Percentage of sales as stipulated in the contract (post-commercialization) |
Asset Status – Hybio’s Semaglutide
- Development Stage: Phase 3 studies completed — among the most advanced generic semaglutide programs in China
- Reference Products: Novo Nordisk’s Ozempic (glycemic control) and Wegovy (weight management)
- Existing Partnership: Collaboration for the weight management indication already in place since May 2024; this new agreement completes the pairing across both blockbuster indications
Market Impact & Outlook
- GLP-1 Generic Race: Semaglutide generics represent one of China’s most fiercely contested pharmaceutical battlegrounds, with the molecule’s patent cliff approaching and both glycemic control and weight management demand expanding rapidly.
- Indication-Split Licensing Model: By separating glycemic control and weight management into distinct collaborations, Hybio optimizes partner selection per commercial channel and indication-specific market dynamics.
- Deal Economics: With upfront, regulatory, supply, and sales milestones totaling up to approximately RMB 182.5 million plus royalties, the structure preserves Hybio’s upside while shifting commercialization execution and costs to Wansheng Pharmaceutical.
- Next Steps: Regulatory submission and approval timelines for the glycemic control indication were not disclosed.
Forward‑Looking Statements
This brief contains forward-looking statements regarding the development and commercialization of Hybio’s semaglutide for glycemic control. Actual results may differ due to risks including regulatory outcomes, pricing and reimbursement dynamics, and competitive intensity in the GLP-1 market.-Fineline Info & Tech